TMCnet News
Epizyme Announces Clinical Data from Phase 1 Trial of EZH2 Inhibitor EPZ-6438 (E7438) to be Presented at EORTC-NCI-AACR SymposiumCAMBRIDGE, Mass. --(Business Wire)-- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced, in conjunction with its development partner Eisai, that clinical data from the ongoing Phase 1 study of EPZ-6438 (E7438), an oral, small molecule inhibitor of EZH2, will be featured in a late-breaking oral presentation at the 26th EORTC-AACR-NCI Symposium on Molecular Targets and Cancer Therapeutics, to be held November 18-21 in Barcelona, Spain. The presentation will take place during the plenary session on Epigenetic Targets. In addition, this session will feature a presentation from Chief Scientific Officer Robert Copeland, Ph.D., discussing Epizyme's targeted therapies against the histone methyltransferases (HMTs) DOT1L and EZH2. "Preliminary observations of activity and tolerability suggested the potential utility for EPZ-6438 in a broader range of patients than simply those with EZH2-mutated lymphoma," said Peter Ho, M.D., Ph.D., Chief Development Officer, Epizyme. "The presentation at the EORTC-NCI-AACR Symposium will include results from EZH2 mutant and wild-type patients, and we look forward to presenting these data."
Phase 1 first-in-human study of the enhancer of zeste-homolog 2
(EZH2) histone methyl transferase inhibitor E7438 as a single agent in
patients with advanced solid tumors or B cell lymphoma
DOT1L and EZH2 targeted therapies About EZH2 Cancers EZH2 is a histone methyltransferase (HMT) that is increasingly understood to play a potentially oncogenic role in a number of cancers. These include germinal center (GC) non-Hodgkin lymphomas, INI1-deficient cancers such as synovial sarcoma and malignant rhabdoid tumors, and a range of other solid tumors. About EPZ-6438 Epizyme and our partner Eisai are developing EPZ-6438 (Eisai refers to this therapeutic candidate as E7438), a small molecule inhibitr of EZH2 created with our proprietary product platform, for the treatment of non-Hodgkin lymphoma patients. In many human cancers, misregulated EZH2 enzyme activity results in misregulation of genes that control cell proliferation - without these control mechanisms, cancer cells are free to grow rapidly. Epizyme granted Eisai a worldwide license to EPZ-6438 (E7438), subject to Epizyme's right to opt in for co-development, co-commercialization and profit share arrangement with Eisai in the United States. Epizyme is working with Roche and Eisai to develop a companion diagnostic to identify patients with non-wild type EZH2, where EZH2 contains point mutations. Additional information about these partnerships may be found here: http://www.epizyme.com/about-us/partnerships/ In June 2013, Epizyme and Eisai initiated a Phase 1/2 clinical trial of EPZ-6438 (E7438) in patients with advanced solid tumors or B-cell lymphomas. EPZ-6438 is the second HMTi to enter human clinical development (following Epizyme's DOT1L inhibitor, EPZ-5676). Additional information about this program, including clinical trial information, may be found here: http://clinicaltrials.gov/ct2/show/NCT01897571?term=7438&rank=1
About Epizyme, Inc. For more information, visit www.epizyme.com and connect with us on Twitter (News - Alert) at @EpizymeRx.
Cautionary Note on Forward-Looking Statements
|